Blood Res.  2019 Dec;54(4):290-295. 10.5045/br.2019.54.4.290.

Differential impact of anti-thymocyte globulin dosing by disease risk index in alternative donor peripheral blood stem cell transplantation in patients with acute leukemia or myelodysplastic syndrome after reduced intensity conditioning

• Choi M
• Shin DY
• Lee JY
• Kim I
• Yoon SS
• Bang SM

• KMID: 2466598
• DOI: http://doi.org/10.5045/br.2019.54.4.290

Abstract

No abstract available.

MeSH Terms

Antilymphocyte Serum*
Humans
Leukemia*
Myelodysplastic Syndromes*
Peripheral Blood Stem Cell Transplantation*
Tissue Donors*
Antilymphocyte Serum

Figure

• 

  Fig. 1 Graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS), disease-free survival (DFS), and overall survival (OS) by total dose of anti-thymocyte globulin (ATG) in the overall population (A–C), in subgroups with low/intermediate disease risk indices (DRI; D–F), and in subgroups with high/very high DRI (G–I).

Reference

1. Arai S, Arora M, Wang T, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015; 21:266–274.

2. Baron F, Mohty M, Blaise D, et al. Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017; 102:224–234.

3. Kumar A, Reljic T, Hamadani M, Mohty M, Kharfan-Dabaja MA. Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. Bone Marrow Transplant. 2019; 54:1094–1106.

4. Remberger M, Ringden O, Hägglund H, et al. A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors. Clin Transplant. 2013; 27:E368–E374.

5. Chang YJ, Wang Y, Mo XD, et al. Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial. Cancer. 2017; 123:2881–2892.

6. Kim T, Choi Y, Lee JH, et al. Clinical impact of anti-thymocyte globulin on survival and graft-versus-host disease in patients undergoing human leukocyte antigen mismatched allogeneic stem cell transplantation. Korean J Intern Med. 2019; [Epub ahead of print].

7. Valcarcel D, Martino R, Caballero D, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol. 2008; 26:577–584.

8. Thepot S, Zhou J, Perrot A, et al. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. Leukemia. 2010; 24:1852–1858.